Results 211 to 220 of about 36,160 (268)
Some of the next articles are maybe not open access.
Pneumococcal conjugate vaccines
Immunology Letters, 1991We have prepared conjugates of pneumococcal type 4 polysaccharides (PS4) or oligosaccharides to tetanus toxoid using the carbodiimide method. The use of a spacer, 6-aminohexanoic acid, resulted in higher incorporation of carrier protein. Conjugates contained up to 10% free polysaccharide, but no free protein.
C C, Peeters +6 more
openaire +4 more sources
Conjugated Heptavalent Pneumococcal Vaccine
The Annals of Pharmacotherapy, 2002OBJECTIVE: To review the immunogenicity, efficacy, and safety of the heptavalent conjugated pneumococcal vaccine (PCV7). DATA SOURCES: A MEDLINE search (1993–August 2001) of research limited to humans published in the English language was conducted. STUDY SELECTION: Findings from randomized, controlled, multicenter trials were reviewed.
Vinita B, Pai +2 more
openaire +2 more sources
Pneumococcal conjugate vaccine
Current Opinion in Pediatrics, 2001Pneumococcal infections account for a significant proportion of bacterial infections in infants and children. The growing threat from pneumococci resistant to penicillin and other antimicrobials has led to increased pressure for the development of an effective vaccine.
openaire +4 more sources
Pneumococcal conjugated vaccine: PHiD-CV
Expert Review of Anti-infective Therapy, 2009At the beginning of a new century, we have gained significant achievements against pneumococcal infections by using conjugated pneumococcal vaccines. In January 2009, the EMEA issued a positive opinion about, and recommended the approval of, GlaxoSmithKline's pediatric pneumococcal candidate vaccine, which is indicated for active immunization against ...
Ener Cagri, Dinleyici +1 more
openaire +2 more sources
The pneumococcal protein conjugate vaccines
The Journal of Pediatrics, 2000to develop the first licensed pneumococcal vaccine, consisting of 14 purified capsular polysaccharide antigens representing the most prevalent disease-associated serotypes. Coverage was improved by the addition of 9 more purified polysaccharide antigens, resulting in the currently licensed 23valent pneumococcal capsular polysaccharide vaccine.
T R, Peters, K M, Edwards
openaire +2 more sources
Pneumococcal Conjugate Vaccines
1995The development of multivalent pneumococcal vaccines for the prevention of both systemic and noninvasive pneumococcal diseases in infants, older adults, and immunecompromised individuals has gained increasing importance over the last decade. The rising cost of medical care has renewed interest in prevention instead of cure for a disease and in many ...
openaire +2 more sources
Immunogenicity of pneumococcal conjugate vaccines
The Pediatric Infectious Disease Journal, 2000Prevention of pneumococcal infections is a public health priority because of the high impact of the disease and because of the increasing problems due to antimicrobial resistance. Traditional vaccines, consisting of purified capsular polysaccharides (PSs) of Streptococcus pneumoniae, are not immunogenic in young children.
openaire +2 more sources
Conjugate pneumococcal vaccines: an overview
Medical Journal of Australia, 2000A seven-valent conjugate pneumococcal vaccine has been shown to have dramatic efficacy against invasive pneumococcal disease and lesser efficacy against otitis media and pneumonia. This vaccine was licensed for use in infants in the United States in February 2000 and is recommended there for routine use in infants and catch-up vaccination in high-risk ...
openaire +2 more sources
Pneumococcal Conjugate Vaccines
Pediatric Annals, 1999J, Eskola, M, Anttila
openaire +4 more sources